News Image

Why MERCK & CO. INC. (NYSE:MRK) should be investigated by quality investors.

By Mill Chart

Last update: Aug 28, 2023

Quality investors are looking for the best of the best. Companies which are growing steadily and consistently, but are also in excellent financial condition. We will have a look here to see if MERCK & CO. INC. (NYSE:MRK) is suited for quality investing. Investors should of couse do their own research, but we spotted MERCK & CO. INC. showing up in our Caviar Cruise quality screen, so it may be worth spending some more time on it.

Why NYSE:MRK may be interesting for quality investors.

  • MERCK & CO. INC. has shown strong performance in revenue growth over the past 5 years, with a 8.12% increase. This indicates the company's ability to generate consistent revenue growth and reflects its potential for long-term success.
  • The ROIC excluding cash and goodwill of MERCK & CO. INC. stands at 21.93%, reflecting the company's strong financial management and profitability. This metric underscores its ability to generate favorable returns on the capital invested in its core operations.
  • With a favorable Debt/Free Cash Flow Ratio of 3.41, MERCK & CO. INC. showcases its sound financial discipline and cash flow management. This ratio indicates the company's ability to service its debt obligations while maintaining sufficient free cash flow for future investments or operational needs.
  • The Profit Quality (5-year) of MERCK & CO. INC. stands at 97.79%, highlighting its ability to consistently generate reliable profits. This metric underscores the company's strong business fundamentals and reinforces its position as a financially stable entity.
  • MERCK & CO. INC. has experienced impressive EBIT growth over the past 5 years, with 15.32% increase. This reflects the company's effective operational performance and highlights its potential for long-term financial success.
  • MERCK & CO. INC. has achieved impressive EBIT 5-year growth, surpassing its Revenue 5-year growth. This indicates the company's ability to improve its profitability and operational efficiency, highlighting its strong financial performance.

Fundamental Analysis Observations

ChartMill utilizes a proprietary algorithm to assign a Fundamental Rating to every stock. This rating, ranging from 0 to 10, is computed daily by analyzing a variety of fundamental indicators and properties.

Taking everything into account, MRK scores 6 out of 10 in our fundamental rating. MRK was compared to 214 industry peers in the Pharmaceuticals industry. While MRK has a great profitability rating, there are some minor concerns on its financial health. MRK has a correct valuation and a medium growth rate.

Check the latest full fundamental report of MRK for a complete fundamental analysis.

More quality stocks can be found in our Caviar Cruise screen.

Keep in mind

Important Note: The content of this article is not intended as trading advice. It is essential to perform your own analysis and exercise caution when making trading decisions. The article presents observations created by automated analysis but does not guarantee any trading or investment outcomes. Always trade responsibly and make independent judgments.

Back

MERCK & CO. INC.

NYSE:MRK (4/29/2024, 2:27:09 PM)

129.46

-1.74 (-1.33%)

MRK News

News Image7 hours ago - Merck & Co., Inc.Merck Announces Positive Data for V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults
News Image3 days ago - Investor's Business DailyStock Market Rebounds; Tesla, Microsoft, Google, Meta, Chipotle, GE In Focus: Weekly Review

Microsoft, Tesla, Google, GE and Chipotle were earnings winners. Meta was a notable loser.

News Image3 days ago - Market News VideoInteresting MRK Put And Call Options For June 7th
News Image4 days ago - The Motley FoolMerck (MRK) Q1 2024 Earnings Call Transcript

MRK earnings call for the period ending March 31, 2024.

News Image4 days ago - Market News VideoDow Movers: IBM, MRK
News Image4 days ago - InvestorPlaceMRK Stock Earnings: Merck & Co Beats EPS, Beats Revenue for Q1 2024

MRK stock results show that Merck & Co beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

News Image4 days ago - BloombergMerck Raises Forecast as Sales of Its Cancer Immune Therapy Soar

Merck & Co. raised its annual profit and revenue forecast as the blockbuster cancer drug Keytruda continued to dominate the treatment landscape.

News Image4 days ago - Investor's Business DailyMerck Rides Keytruda To Another Beat-And-Raise, But Diabetes Headwinds Persist

Merck's bread-and-butter cancer drug grew by double digits again in the first quarter.

News Image4 days ago - Merck & Co., Inc.Merck Announces First-Quarter 2024 Financial Results
News Image6 days ago - InvestorPlaceInvestor Alert: Prepare for the Market Crash With These 3 Stocks

These are the low-beta and attractively valued stocks to buy for a market crash as they represent companies with strong fundamentals.

News Image18 days ago - ChartmillWhen you look at NYSE:MRK, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.

MERCK & CO. INC. (NYSE:MRK): good value for what you're paying.

MRK Links
Follow us for more